IL2 and autoimmune disease: However, as recently reported, placebo-controlled phase 2 clinical trials using low dose IL-2, muteins of IL-2, or pegylated IL-2 as a potential therapy to treat autoimmune diseases have not reported statistically significant clinical responses, despite a significant increase in the level of circulating Tregs in the treated patients (5).